Archive — US — turtlesai
1Cell.Ai Launches OncoIncytes: New AI-Powered Oncology Diagnostics
1Cell.Ai launched OncoIncytes, an AI-driven oncology diagnostic platform that integrates single-cell multi-omics to enhance cancer treatment and clinical trial efficacy, backed by a $16 million Series A funding. The platform combines ctDNA, CTC, transcriptomics, and proteomics for precise patient selection and supports antibody-drug conjugate development.
Key points
- 1Cell.Ai launched OncoIncytes for improved cancer diagnostics.
- OncoIncytes integrates single-cell ctDNA, CTCs, RNA transcriptomics, and proteomics.
- The platform utilizes a validated 1,080-gene panel demonstrating 100% concordance with leading NGS panels.
- Supports the development of ADCs by identifying specific protein expressions.
- The company plans U.S. expansion after success in India, funded by a $16 million Series A round.
- The platform is supported by AI/ML models for better data interpretation and clinical decisions.
- Collaboration with major academic institutions like Harvard and Stanford enhances credibility.
- Results are communicated via the iDiscover app for rapid access by healthcare providers.
- 1Cell.Ai's rebranding reflects its commitment to merging scientific and data science expertise.
Why it matters
- The launch of AI-driven diagnostic tools resonates with increasing trends in precision medicine.
- Similar advancements in diagnostics and treatment personalization are expected to grow by 2025.
- AI's role in healthcare continues to expand as major players enter the oncology domain.
- Funding in biotech startups is on the rise, highlighting investor confidence in innovative health technologies.
The launch of OncoIncytes marks a significant advancement in cancer diagnostics, utilizing AI and multi-omics for better patient targeting and treatment outcomes, while reflecting broader trends in precision medicine and the growing role of technology in healthcare.